10 results about "Keratoderma" patented technology

The application discloses application of Pemigatinib or a salt thereof in preparation of a medicine, and the compound is used for treating seborrheic keratosis, preferably seborrheic keratosis related to abnormal activation of a fibroblast growth factor receptor (FGFR) signal pathway, but is not limited to the above mechanism, and specifically, the medicine can inhibit or improve skin hyperplasia and hyperkeratosis lesions driven by FGFR3 gene activating mutation.

To provide a treatment and a diagnosis of autoantibody-mediated eye diseases.SOLUTION: The present disclosure provides an ophthalmic formulation comprising one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount or deleterious actions of autoantibodies on the ocular surface, such as IgG. In particular, the present disclosure provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular disease that can cause symptoms of ocular discomfort, keratitis, dry eye disease, symblepheron formation, fornix foreshortening, eyelid margin / conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.SELECTED DRAWING: None

Topically applied compositions comprising TRPV3 Inhibitors such as KM-001 significantly reduce the severity of dermatological lesions, pruritus, and combinations thereof in patients suffering from dermatological disorders such as keratodermas, lichen simplex chronicus, and ichthyoses.

The invention relates to the technical field of external use medicines, in particular to a compound black bean soup and a processing method thereof, and the formula comprises the following raw materials by weight: A1 10-60g of black beans, A2 3-30g of chaulmoogratree seed pulp, A3 3-30g of bletilla striata, A4 3-30g of cortex dictamni, A5 3-30g of bighead atractylodes rhizome, A6 3-30g of lithospermum, A7 3-30g of rhizoma polygonati, A8 3-30g of rheum officinale, and A9 3-30g of alum. According to the invention, the black bean and the rhizoma polygonati are beneficial to nourishing blood and moistening skin, the bighead atractylodes rhizome is beneficial to invigorating spleen and eliminating dampness, the cortex dictamni and the alum are beneficial to eliminating dampness and relieving itching, the bletilla striata and the lithospermum are beneficial to dispersing blood stasis and promoting tissue regeneration, and the chaulmoogratree seed and the rheum officinale are beneficial to killing insects and promoting fading of hypertrophic skin lesions, so that the black bean Rongshi soup can treat eczema rhagades, palmoplantar keratosis, erythema keratoderma, eczema, eczema, eczema, eczema, eczema, eczema and eczema. The traditional Chinese medicine composition can be used for treating skin diseases such as scale keratotic tinea of hands and feet and the like by nourishing blood and moistening skin, invigorating spleen and eliminating dampness, astringing and promoting tissue regeneration, and killing insects and the like.

The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1 / 2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

To provide a topical formulation containing fluorouracil and not exhibiting contact sensitization.SOLUTION: A pharmaceutical composition for use in treatment of superficial basal cell carcinoma, actinic keratosis, solar keratosis, acne or scars comprises pharmaceutically compatible nanoparticles and at least 0.5 wt.% of fluorouracil, where the nanoparticles comprise at least 50 wt.% of hydrolyzable silicon and are surface-coated with phospholipid, the coated nanoparticles are associated with fluorouracil, the fluorouracil is electrostatically associated with the surface of the nanoparticles and / or the phospholipid bilayer, and the nanoparticles are associated with a willow bark extract.SELECTED DRAWING: None

The present application relates to the field of dermatosis treatment and metabolic regulation, and discloses the use of a HAT modulator combined with an isoprene metabolite in the preparation of a drug for treating porokeratosis. The HAT modulator is preferably a p300 / CBP modulator, including an inhibitor, a degrader, a blocker, an antagonist or a combination thereof. The isoprene metabolite includes one or more of GGPP, FPP, IPP and DMAPP. The present application is based on the imbalance of metabolic flow of the mevalonate (MV) pathway and abnormal epigenetic regulation caused by MVD deficiency, establishes a metabolic-epigenetic coupling imbalance mechanism model, and proposes a combined intervention strategy for metabolic pathways and epigenetic regulation. The combined intervention can improve inflammatory response, abnormal keratinocyte differentiation and imbalance of the PI3K-AKT signal cascade. The combined intervention scheme provided by the present application has a clear mechanism and potential synergistic treatment advantages, and can be used for various types of PK and other inflammatory keratosis related to MV pathway abnormalities.

To provide a method of treating a keratoderma.SOLUTION: The present invention provides a method of treating a keratoderma in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an EGFR inhibitor. Preferably, the EGFR inhibitor is selected from the group consisting of brigatinib, erlotinib, gefitinib, icotinib, lapatinib, sapitinib, vandetanib, varlitinib, afatinib, canertinib, dacomitinib, neratinib, osimertinib, pelitinib, and rociletinib.SELECTED DRAWING: None

This invention relates to the application of hedera saponin A1 in the preparation of drugs for the prevention and / or treatment of seborrheic keratosis or its secondary lesions. Through molecular-level experiments, this invention verifies that hedera saponin A1 can directly bind to the AKT1 protein, inhibiting AKT1-induced upregulation of pro-apoptotic proteins, thereby initiating cell apoptosis. Compared with existing technologies, this invention is a non-invasive treatment, painless, non-invasive, and leaves no scars after healing. Furthermore, this invention has the dual efficacy of "treating seborrheic keratosis" and "chemopreventing malignant transformation." In addition, hedera saponin A1 has a significant killing effect on seborrheic keratosis lesion cells, exhibiting a killing effect on the epidermal layer of isolated seborrheic keratosis lesion tissue, but without inducing significant apoptosis in dermal cells.